N-ACETYLCYSTEINE

Course overview

N-ACETYLCYSTEINE (NAC) IS THE MAINSTAY OF THERAPY FOR ACETAMINOPHEN TOXICITY. NAC HAS FDA APPROVAL FOR THE TREATMENT OF POTENTIALLY HEPATOTOXIC DOSES OF ACETAMINOPHEN (APAP), AND IT IS ALMOST 100% EFFECTIVE IF GIVEN WITHIN 8 HOURS POST-INGESTION. IT IS ALSO APPROVED FOR USE IN CONDITIONS WITH ABNORMAL, VISCID OR INSPISSATED MUCOUS SECRETIONS SUCH AS PNEUMONIA, BRONCHITIS, TRACHEOBRONCHITIS, CYSTIC FIBROSIS, TRACHEOSTOMY PATIENTS, POSTOPERATIVE PULMONARY COMPLICATIONS, POSTTRAUMATIC CHEST CONDITIONS AND BEFORE DIAGNOSTIC BRONCHOSCOPY TO HELP WITH MUCOUS PLUGGING. OFF-LABEL INDICATIONS INCLUDE ACUTE HEPATIC FAILURE, PREVENTION OF CONTRAST-INDUCED NEPHROPATHY AND TOPICAL TREATMENT OF KERATOCONJUNCTIVITIS SICCA. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, MONITORING, AND TOXICITY OF NAC, SO PROVIDERS CAN DIRECT PATIENT THERAPY TO OPTIMAL OUTCOMES WHERE NAC IS INDICATED.